REVIEW ARTICLE |
|
Year : 2021 | Volume
: 153
| Issue : 1 | Page : 17-25 |
|
An overview of preclinical animal models for SARS-CoV-2 pathogenicity
Itti Munshi1, Aditya Khandvilkar1, Shrinivas M Chavan1, Geetanjali Sachdeva1, Smita D Mahale2, Uddhav K Chaudhari1
1 Department of Primate Biology, ICMR-National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India 2 Department of Structural Biology, ICMR-National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India
Correspondence Address:
Dr. Uddhav K Chaudhari Division of Primate Biology, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai 400 012, Maharashtra India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijmr.IJMR_3215_20
|
|
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belonging to the same genus, Betacoronavirus. This relatively new virus has stymied the effective control of COVID-19 pandemic and caused huge social and economic impact worldwide. The FDA-approved drugs were re-purposed to reduce the number of fatalities caused by SARS-CoV-2. However, controversy surrounds about the efficacy of these re-purposed antiviral drugs against SARS-CoV-2.This necessitates the identification of new drug targets for SARS-CoV-2. Hence, the development of pre-clinical animal model is warranted. Such animal models may help us gain better understanding of the pathophysiology of SARS-CoV-2 infection and will be effective tools for the evaluation and licensure of therapeutic strategies against SARS-CoV-2. This review provides a summary of the attempts made till to develop a suitable animal model to understand pathophysiology and effectiveness of therapeutic agents against SARS-CoV-2. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|